Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL14718591

CCCc1cc(Cl)ccc1Cl.N

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 1/20 0.45
FLT4 P35916 1/20 0.45
KDR P35968 1/20 0.45
TP53 P04637 2/20 0.42
KCNH2 Q12809 2/20 0.40
CYP3A4 P08684 3/20 0.39
IDO1 P14902 2/20 0.39
HPGD P15428 2/20 0.39
MEN1 O00255 1/20 0.39
SLC22A1 O15245 1/20 0.39
USP2 O75604 1/20 0.39
LMNA P02545 1/20 0.39
HSP90AA1 P07900 1/20 0.39
MAPT P10636 1/20 0.39
HSPD1 P10809 1/20 0.39
HSPA5 P11021 1/20 0.39
ALOX15 P16050 1/20 0.39
ALOX12 P18054 1/20 0.39
CASP1 P29466 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7224195 0.98 FLT1 (0.46) FLT1FLT4KDRTP53KCNH2
SCHEMBL30645684 0.85 MEN1 (0.44) FLT1FLT4KDRTP53CYP3A4
SCHEMBL8641170 0.85 MEN1 (0.44) FLT1FLT4KDRTP53CYP3A4
SCHEMBL6685016 0.83 TP53 (0.42) TP53KCNH2CYP3A4MEN1MAPT
SCHEMBL5900913 0.82 TYR (0.44) TP53KCNH2CYP3A4MEN1MAPT
SCHEMBL27951034 0.82 TYR (0.44) TP53KCNH2CYP3A4MEN1MAPT
SCHEMBL1310459 0.82 TYR (0.44) TP53KCNH2CYP3A4MEN1MAPT
SCHEMBL5189692 0.82 TYR (0.44) TP53KCNH2CYP3A4MEN1MAPT
SCHEMBL426435 0.80 IDO1 (0.56) TP53CYP3A4IDO1HPGDHTT
SCHEMBL257058 0.79 HTR2A (0.51) FLT1FLT4KDRTP53KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9249147-B2 Tyrosine kinase inhibitors CHEMBRIDGE CORPORATION (US) 2016-02-02 US disclosed
EP-2966076-A1 NOVEL TYROSINE KINASE INHIBITORS ChemBridge Corporation (US) 2016-01-13 EP disclosed
EP-2262807-B1 NOVEL TYROSINE KINASE INHIBITORS CHEMBRIDGE CORP (US) 2015-08-12 EP disclosed
US-20150011539-A1 NOVEL TYROSINE KINASE INHIBITORS CHEMBRIDGE COPRPORATION 2015-01-08 US disclosed
US-8815906-B2 Tyrosine kinase inhibitors CHEMBRIDGE CORPORATION (US) 2014-08-26 US disclosed
US-20130053376-A1 NOVEL TYROSINE KINASE INHIBITORS CHEMBRIDGE COPRPORATION 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150011539-A1 NOVEL TYROSINE KINASE INHIBITORS ABL1, RET, TTBK1 FLT1 171/4885FLT4 268/4885KDR 227/4885
US-20130053376-A1 NOVEL TYROSINE KINASE INHIBITORS ABL1, RET, TTBK1 FLT1 171/4885FLT4 268/4885KDR 227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.